NCT06916416View on ClinicalTrials.gov

Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2028

Conditions
Classical Hodgkin Lymphoma
Interventions
DRUG

Pembrolizumab

6 doses of 200mg Pembrolizumab iv as single agent every three weeks followed by radiotherapy 20Gy

All Listed Sponsors
lead

University of Cologne

OTHER